Parliament backs controversial reform of EU medicines rules

Institution agrees to seek treatment protection periods that industry has warned will hamper innovation

The European Parliament has backed its heath committee’s stance on controversial proposed changes to EU regulations on medicines innovation.

On 10 April, it voted in favour of the stance by a large majority, explaining in an announcement that the proposals “aim to make medicines more available, accessible and affordable while supporting the competitiveness and attractiveness of the EU pharmaceutical industry”.